Propanc Health Group Corporation (Propanc Biopharma, Inc.) — Form 10-Q
Business context and reporting period: The filing is for the quarter ended December 31, 2012, the company’s fiscal second quarter, and includes results for the six months then ended. The registrant is identified in the filing as Propanc Health Group Corporation. It is a development-stage cancer-treatment research company with operations in Australia; it reported no marketed products and no products in clinical trials.
Key financial metrics
| Metric | Period or date | Value |
|---|---|---|
| Revenue | Three and six months ended December 31, 2012 | $0 |
| Operating expenses | Three months / six months ended December 31, 2012 | $446,897 / $942,760 |
| Net loss | Three months / six months ended December 31, 2012 | $387,753 / $880,318 |
| Net loss per share, basic and diluted | Three months / six months ended December 31, 2012 | $0.02 / $0.01 |
| Research and development expense | Six months ended December 31, 2012 | $1,744 |
| Net cash used in operations | Six months ended December 31, 2012 | $77,898 |
| Cash and total assets | December 31, 2012 | $494 / $12,300 |
| Current liabilities | December 31, 2012 | $655,521 |
| Accumulated development-stage deficit | December 31, 2012 | $16,161,032 |
Gross profit and margins are not applicable because the company had no revenue. The filing reports total stockholders’ deficit of $643,221. Current liabilities substantially exceeded current assets of $8,294. No conventional operating debt or liquidity ratios are provided.
Changes versus the prior comparable periods
- For the six months ended December 31, 2012, net loss was $880,318, versus $5,782,033 in the prior-year period; operating expenses were $942,760, versus $5,951,989. Management attributes the expense decline primarily to the prior-year amortization of stock issued for services ($5,640,097).
- For the three months ended December 31, 2012, net loss was $387,753, versus $2,712,127 in the prior-year quarter. The filing attributes the year-over-year reduction largely to stock-related expense timing.
- Cash was $494 at December 31, 2012, compared with $179 at June 30, 2012. Net operating cash use increased to $77,898 from $40,157 in the comparable six-month period; financing provided $74,025.
- Current liabilities increased to $655,521 from $584,187 at June 30, 2012. The $75,000 convertible debenture was converted to common stock during the period; director and other-party loans were added.
The MD&A gives three-month 2011 operating expenses as $2,878,177, while the statement of operations reports $2,879,177; the filing does not reconcile this difference.
Outlook, risks, and unusual items
- Going concern and funding: Management states that substantial doubt exists about the company’s ability to continue as a going concern. It estimated approximately $7.5 million would be needed over the next 12 to 18 months to fund operations and development, and said available cash was insufficient for the next 12 months. It also stated that existing cash was expected to fund operations only until March 2013. Additional financing was being pursued; there is no assurance it will be obtained.
- Development and patent risk: The lead product was in preclinical work, with no products in clinical trials. Development and future profitability depend on financing, progress of the program, patent outcomes, and achieving sales; none is assured. The company was entering national phases for an international patent application.
- Equity-related expenses: The company issued shares for services and to settle payables. It recorded a $43,200 loss on settlement during the six-month period and described additional expense from voluntary price ratchets on converted debentures. Share-based compensation was a major noncash expense.
- Borrowings and related parties: Some director and stockholder loans were past their stated repayment dates or had terms under renegotiation. The balance sheet included $114,847 in director loans, $64,997 due to directors for expenses, and $38,062 in other loans.
- Subsequent events: In January and February 2013, the company reported additional CEO loans and consultant share issuances, including shares used to settle payables; the February settlement produced a reported $64,750 loss.
- Controls: Management concluded disclosure controls were ineffective due to a material weakness: insufficient segregation of duties because of the small staff. Remediation depended on hiring accounting personnel when resources permitted.
- The filing reports no pending or threatened material litigation, no defaults upon senior securities, and no off-balance-sheet arrangements. No specific forward financial guidance was provided.
Investor facts to verify
- How the company planned to fund near-term operations and its stated $7.5 million development requirement, given $494 cash at quarter-end.
- Whether subsequent financing was secured and the status, maturity, interest, and renegotiation of director and stockholder loans.
- Progress of preclinical work, any transition toward clinical trials, and national-phase patent filings and outcomes.
- The extent of potential future dilution from shares issued for services, debt conversions, and price-protection arrangements.
- Whether management remediated the disclosed internal-control material weakness.
- The discrepancy in the MD&A’s three-month prior-year operating expense figure versus the financial statements.